10-Q 1 d99077e10vq.txt FORM 10-Q FOR QUARTER ENDED JUNE 30, 2002 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 (MARK ONE) [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarter Ended June 30, 2002 ------------- or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to -------------- --------------- Commission File Number: 001-12547 --------- ChemFirst Inc. ------------------------ (Exact name of registrant as specified in its charter.) Mississippi 64-0679456 -------------------------------------------------------------------------------- (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 700 North Street, Jackson, MS 39202-3095 -------------------------------------------------------------------------------- (Address of principal (Zip Code) executive offices) Registrant's Telephone Number, including Area Code: 601/948-7550 ------------ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes X No --- --- Class Outstanding at July 31, 2002 -------------------------- ---------------------------- Common Stock, $1 Par Value 14,246,940 ChemFirst Inc. Consolidated Balance Sheets (Unaudited) (In Thousands of Dollars)
June 30 December 31 2002 2001 ------------ ------------ Assets: Current assets Cash and cash equivalents $ 58,912 43,864 Accounts receivable 40,696 36,582 Inventories: Finished products 37,096 35,157 Work in process 829 828 Raw materials and supplies 13,405 12,475 ------------ ------------ Total inventories 51,330 48,460 ------------ ------------ Prepaid expenses and other current assets 7,956 7,690 ------------ ------------ Total current assets 158,894 136,596 ------------ ------------ Goodwill, net 13,724 13,724 Intangible assets, net 100 120 Investments and other assets 989 1,045 Property, plant and equipment 312,058 304,483 Less: accumulated depreciation and amortization 162,933 153,524 ------------ ------------ Property, plant and equipment, net 149,125 150,959 ------------ ------------ $ 322,832 302,444 ============ ============ Liabilities and Stockholders' Equity: Current liabilities Notes payable $ 18,530 7,916 Deferred revenue 2,222 890 Accounts payable 13,574 14,446 Accrued expenses and other current liabilities 14,802 17,240 ------------ ------------ Total current liabilities 49,128 40,492 ------------ ------------ Long-term debt 4,889 4,755 Other long-term liabilities 32,530 27,647 Deferred income taxes 10,241 9,660 Stockholders' equity: Common stock 14,174 14,053 Additional paid-in capital 32,009 29,398 Unearned compensation (593) (683) Accumulated other comprehensive income (1,832) 1,368 Retained earnings 182,286 175,754 ------------ ------------ Total stockholders' equity 226,044 219,890 ------------ ------------ $ 322,832 302,444 ============ ============
The accompanying notes are an integral part of these financial statements. ChemFirst Inc. Consolidated Statements of Operations (Unaudited) (In Thousands of Dollars and Shares, Except Per Share Amounts)
3 Months Ended 6 Months Ended June 30 June 30 -------------------------- ------------------------- 2002 2001 2002 2001 ---------- ---------- ---------- ---------- Sales $ 74,555 89,009 137,026 180,683 Cost of sales 52,066 72,215 96,031 141,779 ---------- ---------- ---------- ---------- Gross margin 22,489 16,794 40,995 38,904 General, selling and administrative expenses 15,355 15,366 28,468 30,262 Research and development expenses 1,841 1,969 3,611 4,053 Loss on disposal and costs to exit business -- (27,502) -- (27,502) Other operating income, net 921 591 5,908 5,528 ---------- ---------- ---------- ---------- Operating earnings (loss) 6,214 (27,452) 14,824 (17,385) Interest income 257 77 485 127 Interest expense 315 802 476 1,641 Other income (expense), net (19) 1,106 14 1,067 ---------- ---------- ---------- ---------- Earnings (loss) before income taxes 6,137 (27,071) 14,847 (17,832) Income tax expense (benefit) 2,271 (10,151) 5,493 (6,687) ---------- ---------- ---------- ---------- Net earnings (loss) $ 3,866 (16,920) 9,354 (11,145) ========== ========== ========== ========== Basic earnings (loss) per common share: $ 0.27 (1.19) 0.66 (0.79) ========== ========== ========== ========== Average shares outstanding 14,136 14,172 14,098 14,164 Earnings (loss) per common share, assuming dilution: $ 0.27 (1.19) 0.65 (0.79) ========== ========== ========== ========== Average shares outstanding, assuming dilution 14,455 14,172 14,362 14,164 Cash dividend declared per share $ 0.10 0.10 0.20 0.20 ========== ========== ========== ==========
The accompanying notes are an integral part of these financial statements. ChemFirst Inc. Consolidated Statements of Cash Flows (Unaudited) (In Thousands of Dollars)
6 Months Ended June 30 -------------------------- 2002 2001 ---------- ---------- Cash flows from operations: Net earnings (loss) $ 9,354 (11,145) Adjustments to reconcile net earnings (loss) to net cash provided by operations: Depreciation and amortization 9,707 14,537 Provision for losses on receivables 496 -- Loss on disposal and costs to exit business -- 27,502 Deferred taxes and other items 4,914 (11,068) Change in current assets and liabilities, net of effects of dispositions (10,432) (13,825) ---------- ---------- Net cash provided by operating activities 14,039 6,001 ---------- ---------- Cash flows from investing activities: Capital expenditures (7,575) (9,807) Other investing activities -- 1,638 ---------- ---------- Net cash used in investing activities (7,575) (8,169) ---------- ---------- Cash flows from financing activities: Net borrowings on notes payable 8,909 9,589 Dividends (2,822) (2,825) Proceeds from issuance of common stock 2,520 381 ---------- ---------- Net cash provided by financing activities 8,607 7,145 ---------- ---------- Effect of exchange rate changes on cash (23) (487) ---------- ---------- Net increase in cash and cash equivalents 15,048 4,490 Cash and cash equivalents at beginning of period 43,864 5,594 ---------- ---------- Cash and cash equivalents at end of period $ 58,912 10,084 ========== ========== Supplemental disclosures of cash flow information Cash paid during the period for: Interest, net of amounts capitalized $ 479 1,441 ========== ========== Income tax payments (refunds), net $ 6,536 1,551 ========== ==========
The accompanying notes are an integral part of these financial statements. ChemFirst Inc. and Subsidiaries Notes to Consolidated Financial Statements (Unaudited. In Thousands of Dollars) Note 1 - General The financial statements included herein are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial reporting and Securities and Exchange Commission regulations. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. Certain prior year amounts have been reclassified to conform to the 2002 presentation. In the opinion of management, the financial statements reflect all adjustments (all are of a normal and recurring nature) which are necessary to present fairly the financial position, results of operations and cash flows for the interim periods. These financial statements should be read in conjunction with the Annual Report and Form 10-K of the Company for the year ended December 31, 2001. Note 2 - Disposals The Company sold its custom and fine chemical business effective June 30, 2001. Revenues and pretax operating losses of custom and fine chemicals operations for the six-months ended June 30, 2001, were $31,271 and $1,911, respectively, and for the second quarter of the prior year were $14,252 and $3,507, respectively. Note 3 - Intangibles Effective January 1, 2002, the Company adopted Statement of Financial Accounting Standards (SFAS) No. 142, "Goodwill and other Intangible Assets". SFAS No. 142 requires that goodwill and intangible assets with indefinite useful lives no longer be amortized, but instead be tested for impairment at least annually in accordance with the provisions of SFAS No. 142. SFAS No. 142 also requires that intangible assets with estimable useful lives be amortized over the respective estimated useful lives to their estimated residual values, and reviewed for impairment in accordance with SFAS No. 121, "Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to be Disposed Of", or as described below, SFAS No. 144, "Accounting for the Impairment or Disposal of Long-Lived Assets". The Company evaluated its intangible assets excluding goodwill, and determined that all such assets have determinable lives. The Company completed an impairment analysis of goodwill and found no instances of impairment of its recorded goodwill as of January 1, 2002. The Company's goodwill relates to the electronic chemicals and other specialty chemical segment. There were no acquisitions of intangible assets during the quarter ending June 30, 2002. 5 The components of intangible assets are as follows:
June 30, 2002 December 31, 2001 ------------------------------------- ------------------------------------- Gross Net Gross Net Carrying Accumulated Carrying Carrying Accumulated Carrying Amount Amortization Amount Amount Amortization Amount --------- ------------ --------- --------- ------------ --------- Amortized intangibles Loan Costs $ 170 158 12 170 141 29 Other 150 62 88 150 59 91 --------- --------- --------- --------- --------- --------- $ 320 220 100 320 200 120 --------- --------- --------- --------- --------- --------- Intangible assets not Subject to Amortization $ 26,311 12,587 13,724 26,311 12,587 13,724 ========= ========= ========= ========= ========= =========
Aggregate amortization expense for the six-month period ended June 30, 2002 was $20. Amortization expense for the net carrying amount of intangible assets is estimated to be $33 for the remainder of fiscal 2002, $23 in fiscal 2003, $23 in fiscal 2004, $17 in fiscal 2005, and $4 in fiscal 2006. The following table adjusts earnings and earnings per share for the adoption of SFAS No. 142:
Three Months Six Months Ended June 30, Ended June 30, ------------------------- ------------------------- 2002 2001 2002 2001 ---------- ---------- ---------- ---------- Reported net earnings (loss) $ 3,866 (16,920) 9,354 (11,145) Add back goodwill amortization, net of tax -- 237 -- 477 ---------- ---------- ---------- ---------- Adjusted net earnings (loss) $ 3,866 (16,683) 9,354 (10,668) ========== ========== ========== ========== Basic earnings per share: Reported basic earnings per share $ 0.27 (1.19) 0.66 (0.79) Add back goodwill amortization, net of tax -- 0.01 -- 0.04 ---------- ---------- ---------- ---------- Adjusted basic earnings per share $ 0.27 (1.18) 0.66 (0.75) ========== ========== ========== ========== Diluted earnings per share: Reported diluted earnings per share $ 0.27 (1.19) 0.65 (0.79) Add back goodwill amortization, net of tax -- .01 -- 0.04 ---------- ---------- ---------- ---------- Adjusted diluted earnings per share $ 0.27 (1.18) 0.65 (0.75) ========== ========== ========== ==========
6 Note 4 - New Accounting Pronouncements In July 2001, the FASB issued SFAS No. 143, "Accounting for Asset Retirement Obligations". This standard requires entities to record the fair value of a liability for an asset retirement obligation in the period in which it is incurred. When a liability is initially recorded, an entity must capitalize the cost by increasing the carrying amount of the related long-lived asset. Over time, the liability is accreted to its present value each period, and the capitalized cost is depreciated over the useful life of the related asset. Upon settlement of the liability, an entity either settles the obligation for its recorded amount or incurs a gain or loss upon settlement. The Company is required to adopt the provisions of SFAS No. 143 for fiscal years beginning after June 15, 2002. The Company is currently assessing whether SFAS No. 143 will have an impact on its financial statements. In August 2001, the FASB issued SFAS No. 144, "Accounting for the Impairment or Disposal of Long-Lived Assets", which supersedes both SFAS No. 121 and the accounting and reporting provisions of APB Opinion No. 30, "Reporting and Results of Operations - Reporting the Effects of Disposal of a Segment of a Business, and Extraordinary, Unusual and Infrequent Occurring Events and Transactions" (Opinion No. 30), for the disposal of a segment of a business (as previously defined in that Opinion). SFAS No. 144 provides guidance on how a long-lived asset that is used as part of a group should be evaluated for impairment, establishes criteria for when a long-lived asset is held for sale, and prescribes the accounting for a long-lived asset that will be disposed of other than by sale. SFAS No. 144 retains the basic provisions of Opinion No. 30 on how to present discontinued operations in the income statement but broadens that presentation to include a component of an entity (rather than a segment of a business). Unlike SFAS No. 121, an impairment assessment under SFAS No. 144 will not result in a write-down of goodwill. Rather, goodwill is evaluated for impairment under SFAS No. 142, "Goodwill and other Intangible Assets". Effective January 1, 2002, the Company adopted the provisions of SFAS No. 144. The implementation of this statement did not have a significant impact on the Company's financial statements. In July 2002, the FASB issued SFAS No. 146, "Accounting for Costs Associated with Exit or Disposal Activities". Under this standard, commitment to a plan to exit an activity or dispose of long-lived assets will no longer be enough to record a one-time charge for most anticipated costs. Instead, companies will record exit or disposal costs when they are "incurred" and can be measured at fair value, and subsequently adjust the recorded liability for changes in estimated cash flows. The new requirements are effective prospectively for exit or disposal activities initiated after December 31, 2002. The new statement grandfathers the accounting for liabilities that the Company had previously recorded under EITF 94-3. The Company is in the process of reviewing this new statement to determine its potential impact. Note 5 - Comprehensive Income Total comprehensive income (loss) for the three months ended June 30, 2002 and 2001, was $2,672 and ($16,204), respectively. Cumulative comprehensive income (loss) for the six months ended June 30, 2002 and June 30, 2001, was $6,155 and ($10,807), respectively. Total comprehensive income for the Company includes net income and foreign currency translation adjustments. 7 Note 6 - Commitments and Contingencies For the quarter ended June 30, 2002, the Company recorded business interruption insurance recoveries of $364 and for the six months ended June 30, 2002 and 2001, has recorded $3,458 and $3,600, respectively, related to an explosion at the Nissin Chemical plant in Japan, which disrupted the Company's supply of hydroxylamine. No business interruption insurance recoveries were recorded during the three months ended June 30, 2001. From June 2000 through June 30, 2002, $16,000 has been received and recorded, after meeting the one-time $1,000 deductible, under the Company's primary insurance policy. The Company is presently seeking additional recoveries under this policy of $9,000 through arbitration. The Company has received $364 under a separate policy that covers operations in Scotland and continues in negotiations with the carrier toward further recoveries. These amounts are reflected in the consolidated statements of operations as Other Operating Income. On December 31, 1997, the Company purchased through its wholly owned subsidiary, EKC Technology, Inc. ("EKC"), the CMP business of Baikowski International Corporation ("BIC"), a wholly owned subsidiary of Group PSB Industries, S.A. ("PSB"). The purchase price included contingent consideration based on future EKC earnings, with the minimum required contingent consideration of $5,000, estimated to be paid as early as December 2002 by lump sum, recorded at the time of the acquisition. Under provisions of the purchase agreement, BIC has now elected for the contingent consideration to be paid over three consecutive years beginning December 31, 2002, within 60 days following each year end, based on a contractual formula tied to the earnings of EKC for each of those years. Any amounts paid in excess of the $5,000 will be recorded as additional purchase consideration. Note 7 - Subsequent Events On July 23, 2002, the Company entered into a merger agreement with E. I. du Pont de Nemours and Company ("DuPont"), providing for the purchase of the Company's outstanding common stock by DuPont. In accordance with the terms of the merger agreement, each outstanding share of the Company's common stock would be converted into the right to receive $29.20 in cash. Completion of the transaction is subject to shareholder and certain regulatory approval. 8 Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations Results of Operations - Six months ended June 30, 2002 Compared to the six months ended June 30, 2001 Consolidated Results Net earnings for the six months ended June 30, 2002 were $9.4 million or $0.65 per diluted share, versus a loss of $11.1 million or $0.79 per share for the same period of the prior year. Prior year results include an after-tax loss of $17.2 million or $1.21 per share from the disposition of the Company's custom and fine chemical business, after-tax losses of $1.2 million or $0.10 per share on $31.3 million in sales related to their operations and a gain of $0.7 million or $0.05 per share on the sale of the Company's interest in a captive insurance company. Prior year earnings excluding these special items were $6.6 million or $0.47 per share. Results for the current and prior year also include after-tax business interruption insurance payments of $2.2 million or $0.15 per share and $2.2 million or $0.16 per share, respectively. The current year earnings improvement was due to better results in both electronic and other specialty and polyurethane chemicals and lower interest expense. Excluding prior year fine chemical operations, sales declined 8% for the current year as a 17% decline in polyurethanes was partially offset by a 4% increase in electronic and other specialties, and general, sales and administrative expenses rose 6% due to higher unallocated corporate expenses. Segment Operations Segment Information (In Thousands of Dollars)
6 Months Ended June 30 2002 2001 ---------- ---------- Sales: Electronic and Other Specialty Chemicals $ 65,495 94,362 Polyurethane Chemicals 71,531 86,321 ---------- ---------- Total $ 137,026 180,683 ========== ========== Operating profit (loss) before income taxes: Electronic and Other Specialty Chemicals $ 7,835 (22,735) Polyurethane Chemicals 14,901 12,023 ---------- ---------- 22,736 (10,712) Unallocated corporate expenses (7,912) (6,673) Interest income (expense), net 9 (1,514) Other income, net 14 1,067 ---------- ---------- Earnings (loss) before income taxes $ 14,847 (17,832) ========== ==========
9 Electronic and Other Specialty Chemicals results for the current six months were an operating profit of $7.8 million versus a loss of $22.7 million for the prior year. Prior year results include a $27.5 million pretax loss from the Company's decision to exit and dispose of its custom and fine chemical operations in June of 2001, and custom and fine chemical operating losses of $2.0 million on $31.3 million in sales. Excluding these losses and revenue in the prior year, operating profit for the six months of the current year was up 17% over prior year's $6.7 million as higher sales and gross margins more than offset a $0.8 million increase in other net operating expenses. Sales were up 4%, from $63.1 million to $65.5 million, with gross margins increasing to 37% of sales versus 35%. Sales and margins were up primarily due to higher electronic chemical volume. Net other operating expense rose on a 2% increase in expenses and lower royalty income. Results include pretax business interruption payments of $3.5 million and $3.6 million for the current year and prior year, respectively, related to the June 2000 plant explosion at a critical raw material supplier. Polyurethane Chemicals pretax operating profits for the six months were $14.9 million, up from $12.0 million for the same period in the prior year, reflecting higher margins and royalty income from a process technology license. Sales were off 17% to $71.5 million due to the pass-through of lower energy and raw materials costs on contract sales and a 6% decrease in volume. Gross margins as a percentage of sales increased to 23% for the current year, up from 17% for the prior year, primarily reflecting favorable energy and raw material pass-throughs. Unallocated corporate expense for the current year was $7.9 million, up from the prior year's $6.7 million, primarily due to a $1.6 million increase in accruals for benefit plans indexed to the Company's stock price. Net interest expense was down $1.5 million from the prior year on lower average debt and increased interest income from the proceeds of the custom and fine chemicals disposal. Results of Operations - Three months ended June 30, 2002 Compared to the three months ended June 30, 2001 Consolidated Results Net earnings for the three months ended June 30, 2002 were $3.9 million or $0.27 per diluted share, versus a loss of $16.9 million or $1.19 per share for the same period of the prior year. Prior year results include an after-tax loss of $17.2 million or $1.21 per share from the disposition of the Company's custom and fine chemical business, after-tax losses of $2.2 million or $0.16 per share related to their operations and a gain of $0.7 million or $0.05 per share on the sale of the Company's interest in a captive insurance company. Results for the current year also include after-tax business interruption insurance payments of $0.2 million or $0.02 per share. Prior year results excluding these special items were $1.8 million or $0.13 per share. Excluding special items, earnings were up as better results in both electronic and other specialty and polyurethane chemicals and lower net interest expense more than offset higher other operating expenses. Excluding fine chemicals, sales versus prior year were essentially unchanged as a $4.9 million decrease in polyurethane sales was offset by an increase in electronic and other specialties and general, selling and administrative expenses rose 13%, primarily due to higher unallocated corporate expenses. 10 Segment Operations Segment Information (In Thousands of Dollars)
3 Months Ended June 30 -------------------------- 2002 2001 ---------- ---------- Sales: Electronic and Other Specialty Chemicals $ 32,580 42,162 Polyurethane Chemicals 41,975 46,847 ---------- ---------- Total $ 74,555 89,009 ========== ========== Operating profit (loss) before income taxes: Electronic and Other Specialty Chemicals $ 2,321 (31,067) Polyurethane Chemicals 8,561 6,909 ---------- ---------- 10,882 (24,158) Unallocated corporate expenses (4,668) (3,294) Interest income (expense), net (58) (725) Other income (expense), net (19) 1,106 ---------- ---------- Earnings (loss) before income taxes $ 6,137 (27,071) ========== ==========
Electronic and Other Specialty Chemicals results for the current three months were an operating profit of $2.3 million versus a loss of $31.1 million for the prior year. Prior year results include a $27.5 million pretax loss from the Company's decision to exit and dispose of its custom and fine chemical operations in June of 2001, and custom and fine chemical operating losses of $3.5 million on $14.3 million in sales. Excluding these losses and revenue in the prior year, operating profit for the three months of the current year was up $2.4 million over the prior year's $0.1 million loss on higher sales and gross margins. Sales were up 17%, from $27.9 million to $32.6 million, with gross margins increasing to 38% of sales versus 35%. Sales and margins were up primarily due to higher electronic chemical volume. Demand from the Far East drove record remover sales for the quarter. Results include business interruption payments of $0.4 million for the current year. Polyurethane Chemicals pretax operating profits for the three months were $8.6 million, up from $6.9 million for the same period prior year on improved margins. Sales were off 10% to $42.0 million, as volume declined 8%. Gross margins as a percentage of sales increased to 24% for the current year, up from 18% for the prior year, primarily reflecting favorable energy and raw material pass-throughs. Unallocated corporate expense for the current year was $4.7 million, up from the prior year's $3.3 million, primarily due to a $1.0 million increase in accruals for benefit plans indexed to the Company's stock price. Net interest expense was down $0.7 million from the prior year on lower average debt and increased interest income from the proceeds of the custom and fine chemicals disposal. Other income for the prior year included a $1.1 million gain from the sale of the Company's interest in an offshore captive insurance company. 11 Capital Resources and Liquidity Cash flow from operating activities for the six months ended June 30, 2002, was $14.0 million versus $6.0 million in the prior period. Operating cash flow for the current period reflects higher earnings, while prior period cash flows were decreased by a reduction in payables. Net cash used in investing activities for the current period was $7.6 million versus $8.2 million in the prior period. Capital expenditures in both periods are primarily related to electronic chemical operations. Prior period investing activities also includes $1.6 million in proceeds from the sale the Company's interest in an offshore captive insurance company. Current period financing activities include a $8.9 million increase in yen denominated borrowings to more effectively finance Japanese operations (See Quantitative and Qualitative Disclosures About Market Risk). Forward-Looking Statements Certain statements included in this Form 10-Q which are not historical in nature, may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements, as well as other forward-looking statements made from time to time by the Company, or in the Company's press releases and filings with the U.S. Securities and Exchange Commission, are based on certain underlying assumptions and expectations of management. These forward-looking statements are subject to risks and uncertainties which could cause actual results to differ materially from those expressed in such forward-looking statements. Such risks and uncertainties include, but are not limited to, general economic conditions, availability and pricing of utilities and raw materials, including hydroxylamine, supply/demand balance for key products, new product development, manufacturing efficiencies, conditions of and product demand by key customers, the timely completion and start up of construction projects, pricing pressure as a result of domestic and international market forces and insurance coverage and timing of any claim payments related to the disruption in supply of hydroxylamine, and other factors as may be discussed in the company's Form 10-K for the fiscal year ended December 31, 2001. Item 3. Quantitative and Qualitative Disclosures About Market Risk The Company is exposed to changes in financial market conditions in the normal course of its business, including changes in interest rates and foreign currency exchange rates. At June 30, 2002, the Company had no open derivative instrument contracts. Financial instruments related to foreign operations were limited to short-term debt denominated in Japanese yen with a U.S. dollar equivalent of $18.5 million. An assumed ten percent change in the yen exchange rate from the levels of June 30, 2002 and 2001 (with interest rates assumed constant) based on a strengthened U.S. dollar would result in a $1.9 million and $0.8 million respective decrease in the liabilities of the financial instrument and conversely, based on a weakened U.S. dollar, would result in a $1.9 million and $0.8 million respective increase in the liabilities of the financial instrument. The Company typically utilizes fixed and variable-rate debt to maintain liquidity and fund its domestic business operations, with the terms and amounts based on business requirements, market conditions and other factors. At June 30, 2002, this included long-term, fixed rate debt denominated in U.S. dollars, the fair value of which was approximately $4.9 million. A 100 basis point change in interest rates (all other variables held constant) at June 30, 2002, would result in an approximate $0.1 million annualized change in fair value but would not affect interest expense or cash flow. At June 30, 2002, there was no variable rate debt outstanding. 12 Part II. Other Information Item 4. Submission of Matters to a Vote of Security Holders At the Annual Meeting of Stockholders on May 21, 2002, the Company stockholders, pursuant to proxies solicited under Regulation 14A, elected three directors for terms to expire in 2005, or until their successors are elected and qualify. The following votes were cast: Richard P. Anderson 11,670,369 Shares voted for ---------- 544,506 Shares withheld ---------- Robert P. Guyton 11,670,063 Shares voted for ---------- 544,812 Shares withheld ---------- J. Kelley Williams 11,669,927 Shares voted for ---------- 544,948 Shares withheld ----------
In addition, a resolution was submitted to shareholders for the adoption of an amendment to the ChemFirst Inc. 1998 Long-Term Incentive Plan. The vote was as follows: 1998 Long-Term Incentive Plan Amendment 10,294,752 Shares voted for ---------- 72,126 Shares withheld ---------- 1,850,993 Shares voted against ----------
Item 6. Exhibits and Reports on Form 8-K (a) Exhibits Exhibit 10 - ChemFirst Inc. Benefit Restoration Plan, amended as of May 21, 2002. Exhibit 99 - Certification of CEO and CFO pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. (b) Reports on Form 8-K No report on Form 8-K was filed by the Registrant during the three-months ended June 30, 2002 13 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. CHEMFIRST INC. August 14, 2002 /s/ J. Kelley Williams --------------- --------------------------------------------- Date J. Kelley Williams Chairman and Chief Executive Officer August 14, 2002 /s/ Troy B. Browning --------------- --------------------------------------------- Date Troy B. Browning Controller (Principal Accounting Officer) 14 INDEX TO EXHIBITS
EXHIBIT NUMBER DESCRIPTION ------- ----------- 10 ChemFirst Inc. Benefit Restoration Plan, amended as of May 21, 2002. 99 Certification of CEO and CFO pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
15